Ly49G2 receptor blockade reduces tumor burden in a leukemia model but not in a solid tumor model

Cancer Immunology, Immunotherapy

Volumn 57, Issue 5, 2008, Pages 655-662

  Barber, Melissa A ^a   Zhang, Tong ^a   Gagne, Bethany A ^a   Van Ginderachter, Jo A ^b,c   De Baetselier, Patrick ^b,c   Sentman, Charles L ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^c VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

AKR; Immunotherapy; Lymphoma; Natural Killer Cells; Tumor Immunity

Indexed keywords

IMMUNOGLOBULIN F(AB) FRAGMENT; LY49G2 RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NATURAL KILLER CELL RECEPTOR; RECEPTOR BLOCKING AGENT;

AKR MOUSE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BAGG ALBINO MOUSE; CONTROLLED STUDY; GROWTH INHIBITION; IN VIVO STUDY; LEUKEMIA; LYMPHOMA CELL; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BLOCKING; SOLID TUMOR; TUMOR CELL; TUMOR GROWTH; TUMOR LOCALIZATION; TUMOR MODEL; TUMOR VOLUME;

ANIMALS; ANTIGENS, LY; BASE SEQUENCE; DISEASE MODELS, ANIMAL; FLOW CYTOMETRY; KILLER CELLS, NATURAL; LECTINS, C-TYPE; LEUKEMIA; MICE; MOLECULAR SEQUENCE DATA; NEOPLASMS, EXPERIMENTAL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 43149084350     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-007-0404-2     Document Type: Article

References (44)

1. Bakker AB, Phillips JH, Figdor CG, Lanier LL (1998) Killer cell inhibitory receptors for MHC class I molecules regulate lysis of melanoma cells mediated by NK cells, gamma delta T cells, and antigen-specific CTL. J Immunol 160:5239-5245
2. Bignon JD, Gagne K (2005) KIR matching in hematopoietic stem cell transplantation. Curr Opin Immunol 17:553-559
3. Brennan J, Mahon G, Mager DL, Jefferies WA, Takei F (1996) Recognition of class I major histocompatibility complex molecules by Ly-49: specificities and domain interactions. J Exp Med 183:1553-1559
4. Cerwenka A, Baron JL, Lanier LL (2001) Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo. Proc Natl Acad Sci USA 98:11521-11526
5. Chang CC, Campoli M, Ferrone S (2005) Classical and nonclassical HLA class I antigen and NK Cell-activating ligand changes in malignant cells: current challenges and future directions. Adv Cancer Res 93:189-234
6. Chiang EY, Henson M, Stroynowski I (2002) The nonclassical major histocompatibility complex molecule Qa-2 protects tumor cells from NK cell- and lymphokine-activated killer cell-mediated cytolysis. J Immunol 168:2200-2211
7. Diefenbach A, Jensen ER, Jamieson AM, Raulet DH (2001) Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 413:165-171
8. Fahlen L, Oberg L, Brannstrom T, Khoo NK, Lendahl U,Sentman CL (2000) Ly49A expression on T cells alters T cell selection. Int Immunol 12:215-222
9. Gati A, Guerra N, Giron-Michel J, Azzarone B, Angevin E, Moretta A, Chouaib S,Caignard A (2001) Tumor cells regulate the lytic activity of tumor-specific cytotoxic t lymphocytes by modulating the inhibitory natural killer receptor function. Cancer Res 61:3240-3244
10. Geldhof AB, Moser M, Lespagnard L, Thielemans K, De Baetselier P (1998) Interleukin-12-activated natural killer cells recognize B7 costimulatory molecules on tumor cells and autologous dendritic cells. Blood 91:196-206
11. Geldhof AB, Van Ginderachter J, Vandersteen P, Raes G, De Baetselier P (1998) Multiple effects of transfection with interleukin 2 and/or interferon gamma on the behavior of mouse T lymphoma cells. Clin Exp Metastasis 16:447-459
12. Geldhof AB, Van Ginderachter JA, Liu Y, Noel W, Raes G, De Baetselier P (2002) Antagonistic effect of NK cells on alternatively activated monocytes: a contribution of NK cells to CTL generation. Blood 100:4049-4058
13. Glas R, Sturmhofel K, Hammerling GJ, Karre K, Ljunggren HG (1992) Restoration of a tumorigenic phenotype by beta 2-microglobulin transfection to EL-4 mutant cells. J Exp Med 175:843-846
14. Glas R, Franksson L, Une C, Eloranta ML, Ohlen C, Orn A, Karre K (2000) Recruitment and activation of natural killer (NK) cells in vivo determined by the target cell phenotype. An adaptive component of NK cell-mediated responses. J Exp Med 191:129-138
15. Grundy MA, Sentman CL (2006) Immunodeficient mice have elevated numbers of NK cells in non-lymphoid tissues. Exp Cell Res 312:3920-3926
16. Hanke T, Takizawa H, McMahon CW, Busch DH, Pamer EG, Miller JD, Altman JD, Liu Y, Cado D, Lemonnier FA, Bjorkman PJ, Raulet DH (1999) Direct assessment of MHC class I binding by seven Ly49 inhibitory NK cell receptors. Immunity 11:67-77
17. Hoglund P, Glas R, Ohlen C, Ljunggren HG, Karre K (1991) Alteration of the natural killer repertoire in H-2 transgenic mice: specificity of rapid lymphoma cell clearance determined by the H-2 phenotype of the target. J Exp Med 174:327-334
18. Hoglund P, Ljunggren HG, Ohlen C, Ahrlund-Richter L, Scangos G, Bieberich C, Jay G, Klein G, Karre K (1988) Natural resistance against lymphoma grafts conveyed by H-2Dd transgene to C57BL mice. J Exp Med 168:1469-1474
19. Hsu KC, Keever-Taylor CA, Wilton A, Pinto C, Heller G, Arkun K, O'Reilly RJ, Horowitz MM, Dupont B (2005) Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood 105:4878-4884
20. Igarashi T, Wynberg J, Srinivasan R, Becknell B, McCoy JP Jr, Takahashi Y, Suffredini DA, Linehan WM, Caligiuri MA, Childs RW (2004) Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells. Blood 104:170-177
21. Johansson MH, Hoglund E, Nakamura MC, Ryan JC, Hoglund P (1998) Alpha1/alpha2 domains of H-2D(d), but not H-2L(d), induce "missing self" reactivity in vivo-no effect of H-2L(d) on protection against NK cells expressing the inhibitory receptor Ly49G2. Eur J Immunol 28:4198-4206
22. Kane KP, Lavender KJ, Ma BJ (2004) Ly-49 receptors and their functions. Crit Rev Immunol 24:321-348
23. Karlhofer FM, Ribaudo RK, Yokoyama WM (1992) MHC class I alloantigen specificity of Ly-49+ IL-2-activated natural killer cells. Nature 358:66-70
24. Karre K, Ljunggren HG, Piontek G, Kiessling (1986) Selective rejection of H-2 deficient lymphoma variants suggests alternative immune defense strategy. Nature 319:675-678
25. Koh CY, Ortaldo JR, Blazar BR, Bennett M, Murphy WJ (2003) NK-cell purging of leukemia: superior antitumor effects of NK cells H2 allogeneic to the tumor and augmentation with inhibitory receptor blockade. Blood 102:4067-4075
26. Koh CY, Raziuddin A, Welniak LA, Blazar BR, Bennett M, Murphy WJ (2002) NK inhibitory-receptor blockade for purging of leukemia: effects on hematopoietic reconstitution. Biol Blood Marrow Transplant 8:17-25
27. Koh CY, Blazar BR, George T, Welniak LA, Capitini CM, Raziuddin A, Murphy WJ, Bennett M (2001) Augmentation of antitumor effects by NK cell inhibitory receptor blockade in vitro and in vivo. Blood 97:3132-3137
28. Kumar V, McNerney ME (2005) A new self: MHC-class-I-independent natural-killer-cell self-tolerance. Nat Rev Immunol 5:363-374
29. Lanier LL (2005) NK cell recognition. Annu Rev Immunol 23:225-274
30. Makrigiannis AP, Pau AT, Saleh A, Winkler-Pickett R, Ortaldo JR, Anderson SK (2001) Class I MHC-binding characteristics of the 129/J Ly49 repertoire. J Immunol 166:5034-5043
31. Mason LH, Ortaldo JR, Young HA, Kumar V, Bennett M, Anderson SK (1995) Cloning and functional characteristics of murine large granular lymphocyte-1: a member of the Ly-49 gene family (Ly-49G2). J Exp Med 182:293-303
32. Moretta L, Moretta A (2004) Killer immunoglobulin-like receptors. Curr Opin Immunol 16:626-633
33. Moretta L, Moretta A (2004) Unravelling natural killer cell function: triggering and inhibitory human NK receptors. Embo J 23:255-259
34. Ortaldo JR, Mason AT, Winkler-Pickett R, Raziuddin A, Murphy WJ, Mason LH (1999) Ly-49 receptor expression and functional analysis in multiple mouse strains. J Leukoc Biol 66:512-520
35. Re F, Staudacher C, Zamai L, Vecchio V, Bregni M (2006) Killer cell Ig-like receptors ligand-mismatched, alloreactive natural killer cells lyse primary solid tumors. Cancer 107:640-648
36. Ruggeri L, Mancusi A, Capanni M, Martelli MF, Velardi A (2005) Exploitation of alloreactive NK cells in adoptive immunotherapy of cancer. Curr Opin Immunol 17:211-217
37. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, Posati S, Rogaia D, Frassoni F, Aversa F, Martelli MF, Velardi A (2002) Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295:2097-2100
38. Schatzle JD, Sheu S, Stepp SE, Mathew PA, Bennett M, Kumar V (1999) Characterization of inhibitory and stimulatory forms of the murine natural killer cell receptor 2B4. Proc Natl Acad Sci USA 96:3870-3875
39. Sentman CL, Barber MA, Barber A, Zhang T (2006) NK cell receptors as tools for cancer immunotherapy. Adv Cancer Res 95:249-292
40. Silver ET, Lavender KJ, Gong DE, Hazes B, Kane KP (2002) Allelic variation in the ectodomain of the inhibitory Ly-49G2 receptor alters its specificity for allogeneic and xenogeneic ligands. J Immunol 169:4752-4760
41. Verheyden S, Bernier M, Demanet C (2004) Identification of natural killer cell receptor phenotypes associated with leukemia. Leukemia 18:2002-2007
42. Wetzler M, Baer MR, Stewart SJ, Donohue K, Ford L, Stewart CC, Repasky EA, Ferrone S (2001) HLA class I antigen cell surface expression is preserved on acute myeloid leukemia blasts at diagnosis and at relapse. Leukemia 15:128-133
43. Yokoyama WM (1998) Natural killer cell receptors. Curr Opin Immunol 10:298-305
44. Yu YY, George T, Dorfman JR, Roland J, Kumar V, Bennett M (1996) The role of Ly49A and 5E6(Ly49C) molecules in hybrid resistance mediated by murine natural killer cells against normal T cell blasts. Immunity 4:67-76